The Cellular Relay: G-Protein Coupled Receptor (GPCR) Signaling Quiz

GPCRs are also known as 7-TM receptors because their polypeptide chain spans the plasma membrane exactly seven times. This unique serpentine structure creates a bundle of alpha-helices that provides a binding pocket for ligands on the extracellular side and a docking site for G-proteins on the intracellular side, allowing the receptor to relay signals across the lipid bilayer.

This is correct. The alpha subunit of a heterotrimeric G-protein is a molecular switch. Once it is activated by exchanging GDP for GTP, it eventually hydrolyzes the GTP back into GDP through its own enzymatic activity. This self-terminating mechanism is vital because it ensures that the signaling cascade only lasts for a limited time after the ligand dissociates from the receptor.

When a Gs-coupled receptor is activated, the alpha subunit travels along the membrane to stimulate the enzyme adenylyl cyclase. This enzyme then converts ATP into the second messenger cyclic AMP (cAMP). This specific pathway is responsible for mediating a wide range of physiological responses, such as the increase in heart rate triggered by adrenaline through beta-adrenergic receptors.

Heterotrimeric G-proteins consist of three distinct subunits: alpha, beta, and gamma. In the inactive state, these three form a complex with GDP bound to the alpha subunit. Upon receptor activation, the alpha subunit releases GDP, binds GTP, and typically dissociates from the beta-gamma dimer, allowing both components to interact with various effector enzymes or ion channels within the cell.

The exchange of GDP for GTP is the critical step in GPCR signaling. GTP binding induces a conformational change in the alpha subunit that lowers its affinity for both the receptor and the beta-gamma dimer. This dissociation releases the "activated" subunits to move within the membrane and interact with downstream targets, effectively amplifying the original signal from a single extracellular ligand.

This statement is false because the "i" in Gi stands for inhibitory. The Gi protein alpha subunit actually inhibits the enzyme adenylyl cyclase, leading to a decrease in the intracellular levels of cyclic AMP. This mechanism is used by various receptors, such as the alpha-2 adrenergic receptor, to dampen cellular excitability or counteract the stimulatory effects of the Gs pathway.

Adenylyl cyclase is the effector enzyme for the Gs and Gi pathways. Its sole function is to catalyze the cyclization of adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP). As a second messenger, cAMP travels through the cytosol to activate Protein Kinase A (PKA), which then phosphorylates numerous target proteins to alter the cell's metabolic or electrical state.

This is true and is a phenomenon known as "receptor pleiotropy" or "signaling bias." While many receptors have a preferred G-protein partner, some can couple to different G-proteins (e.g., both Gs and Gi) depending on factors like the specific ligand bound or the concentration of different G-proteins in a particular cell type. This allows for highly nuanced and tissue-specific responses to the same drug.

Many GPCRs are not completely "silent" in the absence of a ligand; they exist in an equilibrium between active and inactive states. Basal activity is the level of signaling that occurs when no agonist is present. This concept is essential for understanding "inverse agonists," which are drugs that bind to the receptor and reduce this baseline signaling below its natural level.

For a long time, the beta-gamma dimer was thought to be just a structural scaffold, but it is now known to be a potent signaling molecule in its own right. It can directly bind to and regulate the opening or closing of specific ion channels (like K+ channels) and influence the activity of certain isoforms of adenylyl cyclase and phospholipase C, adding another layer of complexity to GPCR signaling.

This is correct and is a major area of modern drug discovery. While Arrestin was originally discovered for its role in stopping G-protein signaling, researchers found it also acts as a scaffold for other pathways, such as the MAP kinase cascade. Drugs that "bias" signaling toward either the G-protein or the Arrestin pathway are being developed to create medications with fewer side effects.

The Gq pathway activates the enzyme phospholipase C, which cleaves a membrane phospholipid into two second messengers: DAG and IP3. IP3 is water-soluble and diffuses to the endoplasmic reticulum, where it binds to ligand-gated channels. This causes a rapid efflux of stored calcium into the cytoplasm, triggering processes like muscle contraction or the secretion of hormones and neurotransmitters.

Desensitization is a multi-step process that limits prolonged signaling. First, G-protein-coupled receptor kinases (GRKs) phosphorylate the intracellular tail of the activated receptor. This allows the protein Arrestin to bind, which physically blocks further G-protein interaction. Finally, the receptor is often pulled inside the cell through endocytosis, a process known as internalization, effectively removing it from the surface.

RGS proteins act as "GTPase-accelerating proteins" (GAPs). They bind to the activated G-protein alpha subunit and significantly speed up its natural ability to hydrolyze GTP into GDP. By doing so, they shorten the duration of the active state, acting as a crucial "brake" on the system to ensure that signaling stops promptly once the external stimulus is removed.

GPCRs respond to an incredibly diverse array of signals, including neurotransmitters like adrenaline, peptide hormones like glucagon, and inflammatory mediators like histamine. Steroid hormones, however, are lipophilic and typically pass through the plasma membrane to bind to intracellular nuclear receptors, rather than surface-bound G-protein coupled receptors.